Abstract
Esophageal carcinoma (EC) is a global health problem, with disappointing 5-year survival rates of only 15-25%. Near-infrared targeted photodynamic therapy (NIR-tPDT) is a novel strategy in which cancer-targeted phototoxicity is able to selectively treat malignant cells. In this in vitro report we demonstrate the applicability of antibody-based NIR-tPDT in esophageal adenocarcinoma (EAC), using the phototoxic compounds cetuximab-IRDye700DX and trastuzumab-IRDye700DX, targeting respectively epidermal growth factor receptor 1 (EGFR) and 2 (HER2). Furthermore, we demonstrate that NIR-tPDT can be made more effective by tyrosine kinase inhibitor (TKI) induced growth receptor upregulation. Together, these results unveil a novel strategy for non-invasive EAC treatment, and by pretreatment-induced receptor upregulation its future clinical application may be optimized.
Original language | English |
---|---|
Pages (from-to) | 29846-29856 |
Number of pages | 11 |
Journal | Oncotarget |
Volume | 8 |
Issue number | 18 |
DOIs | |
Publication status | Published - 13-Mar-2017 |
Keywords
- targeted photodynamic therapy
- esophageal cancer
- epidermal growth factor receptor family (HER-family)
- targeted treatment
- TRASTUZUMAB-BASED PHOTOIMMUNOTHERAPY
- HIGH-GRADE DYSPLASIA
- BARRETTS-ESOPHAGUS
- MONOCLONAL-ANTIBODIES
- BREAST-CANCER
- TUMORS
- EGFR
- HER2
- EXPRESSION
- TRANSDUCTION